S.C. 1396 et seq.), the children's health insurance program established under IC 12-17.6-2, the biosimilar biological products requirements under IC 16-42-25, or the Medicare program (42 U.S.C. 1395 et seq.):(1) the practitioner must:(A) sign on the line under which the words 'May substitute' appear; or(B) for an electronically transmitted prescription, electronically transmit the instruction 'May substitute.'; and(2) the pharmacist must inform the customer of the substitution.(b) This section does not authorize any substitution other than substitution of a generically equivalent drug product.[Pre-1993 Recodification Citation: 16-6-8.1-2(c).]As added by P.L.2-1993, SEC.25. Amended by P.L.239-1999, SEC.7; P.L.291-2001, SEC.233; P.L.204-2005, SEC.10; P.L.96-2014, SEC.5.
Indiana Legal Code